Sign In
Buy DCTH
$10.33
-0.200 (-1.90%)
At Close: Jun 03, 2026
Delcath Systems, Inc. (DCTH) Beats Q4 Earnings and Revenue Estimates
10:20am, Thursday, 06'th Mar 2025
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.48 per share a year ago
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results
08:00am, Thursday, 06'th Mar 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic canc
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic canc
Are You Looking for a Top Momentum Pick? Why Delcath Systems, Inc. (DCTH) is a Great Choice
01:01pm, Monday, 10'th Feb 2025
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 33.74%: Read This Before Placing a Bet
10:56am, Thursday, 06'th Feb 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 33.7% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, th
Biotech walks a 'tightrope' amid unclear funding, regulations
07:06pm, Thursday, 30'th Jan 2025
Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street se
Delcath Systems (DCTH) is on the Move, Here's Why the Trend Could be Sustainable
09:50am, Thursday, 30'th Jan 2025
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in Delcath Systems (DCTH) is Your Friend, Here's Why
09:51am, Tuesday, 14'th Jan 2025
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 03'rd Jan 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic canc
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
08:00am, Monday, 30'th Dec 2024
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic canc
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U
Delcath Begins Platform Expansion With Two Phase 2 Trials
07:50am, Wednesday, 20'th Nov 2024
Delcath's Q3 US sales hit $10 million. This unlocked $25 million in cash from its Tranche B Warrants, which will fund its Phase 2 trials for mCRC and mBC. HEPZATO KIT's hospital rollout is progressing
Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
07:09am, Monday, 18'th Nov 2024
Delcath Systems' Q3 earnings revealed strong growth with $11.2M in revenue, driven by HEPZATO and CHEMOSAT sales, and an 85% gross margin. The company is expanding its commercial footprint with 12 act
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Transcript
12:30pm, Friday, 08'th Nov 2024
Delcath Systems Inc (NASDAQ:DCTH ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Ger
Delcath Systems, Inc. (DCTH) Reports Q3 Loss
10:11am, Friday, 08'th Nov 2024
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.61 per share a year ago.
